Sunitinib therapy for melanoma patients with KIT mutations. Read more about Sunitinib therapy for melanoma patients with KIT mutations.
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Read more about Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Read more about Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Read more about A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Two distinct routes to oral cancer differing in genome instability and risk for cervical node metastasis. Read more about Two distinct routes to oral cancer differing in genome instability and risk for cervical node metastasis.
Targeted therapy for BRAFV600E malignant astrocytoma. Read more about Targeted therapy for BRAFV600E malignant astrocytoma.
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Read more about TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Read more about Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.
Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Read more about Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.
Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Read more about Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.
